

AIVITA Biomedical CEO Dr. Hans Keirstead Joins Human Immunome Project Board of Directors



AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications announced that CEO Dr. Hans Keirstead has joined the board of the esteemed Human Immunome Project. Modeled after the Human Genome Project, the Human Immunome Project is a 501(c)(3) nonprofit organization focused on global scientific collaboration to decode the human immune system. The effort aims to advance the field of immune health and disease prevention through a greater understanding of the underlying mechanisms of immunity.

The Human Immunome Project brings together leading academic research centers, industrial partners, nonprofits, and governments to answer core questions about how the human immune system fights disease. Through its global consortium, the Human Immunome Project is compiling the biggest dataset of biomedicine at a population scale to create an AI model of the human immune system. Such a model could improve the understanding of immune function, as well as improve the speed and efficiency of vaccine testing. The project is also exploring specific initiatives to protect aging populations, newborns, and defend against future pandemics.

“I’m honored to be a part of this significant and necessary project,” said AIVITA CEO Dr. Hans Keirstead. “There is still much to be learn about the immune system and we have every reason to believe that a greater understanding would lead to a new era of improved immune health.”

AIVITA Biomedical is introducing several advancements to the field of immune health. The company recently received clinical approved by the US FDA to run a Phase 3 trial of its personal immunotherapy for glioblastoma multiforme, which showed a 50% increase in survival in Phase 2 testing. The company is also developing a point-of-care-made personalized vaccine which demonstrated improved safety and enhanced cellular immune memory and protection in 97% of evaluable subjects during Phase 1 and 2 COVID-19 trials. Currently under commercial review, the vaccine provides a direct path to cellular immunity and can be rapidly adapted at point-of-care to meet emerging viral strains.

Source: [AIVITA Biomedical](#)

Published on : Mon, 9 Jan 2023